Santen Pharmaceutical Co., Ltd. (SNPHY)
OTCMKTS · Delayed Price · Currency is USD
11.03
-0.21 (-1.88%)
Jul 31, 2025, 3:43 PM EDT
Smartsheet Revenue
In the fiscal year ending March 31, 2025, Santen Pharmaceutical had annual revenue of 300.00B JPY, down -0.65%. Santen Pharmaceutical had revenue of 77.23B in the quarter ending March 31, 2025, a decrease of -2.40%.
Revenue
300.00B JPY
Revenue Growth
-0.65%
P/S Ratio
1.88
Revenue / Employee
77.94M JPY
Employees
3,849
Market Cap
3.78B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 300.00B | -1.96B | -0.65% |
| Mar 31, 2024 | 301.97B | 22.93B | 8.22% |
| Mar 31, 2023 | 279.04B | 12.78B | 4.80% |
| Mar 31, 2022 | 266.26B | 16.65B | 6.67% |
| Mar 31, 2021 | 249.61B | 8.05B | 3.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Santen Pharmaceutical News
- 2 months ago - Santen Pharmaceutical Co., Ltd. reports Q4 results - Seeking Alpha
- 3 years ago - Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha